These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New insights into the regulation of glucagon secretion by glucagon-like peptide-1. Gromada J; Rorsman P Horm Metab Res; 2004; 36(11-12):822-9. PubMed ID: 15655714 [TBL] [Abstract][Full Text] [Related]
4. Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Sinclair EM; Drucker DJ Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875 [TBL] [Abstract][Full Text] [Related]
5. Glucagon, glucagon-like peptide-1 and their receptors: an introduction. Holst JJ Acta Physiol Scand; 1996 Jul; 157(3):309-15. PubMed ID: 8830884 [No Abstract] [Full Text] [Related]
6. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. Alvarez E; Martínez MD; Roncero I; Chowen JA; García-Cuartero B; Gispert JD; Sanz C; Vázquez P; Maldonado A; de Cáceres J; Desco M; Pozo MA; Blázquez E J Neurochem; 2005 Feb; 92(4):798-806. PubMed ID: 15686481 [TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. List JF; Habener JF Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E875-81. PubMed ID: 15140754 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Nauck M Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470 [TBL] [Abstract][Full Text] [Related]
14. ["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?]. Fehmann HC; Göke B Dtsch Med Wochenschr; 1994 Feb; 119(8):275-9. PubMed ID: 8112212 [No Abstract] [Full Text] [Related]
15. Glucagon-like peptide 1(GLP-1) in biology and pathology. Meier JJ; Nauck MA Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282 [TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 does not mediate amylase release from AR42J cells. Zhou J; Montrose-Rafizadeh C; Janczewski AM; Pineyro MA; Sollott SJ; Wang Y; Egan JM J Cell Physiol; 1999 Dec; 181(3):470-8. PubMed ID: 10528233 [TBL] [Abstract][Full Text] [Related]
17. The development of beta-cell mass: recent progress and potential role of GLP-1. Stoffers DA Horm Metab Res; 2004; 36(11-12):811-21. PubMed ID: 15655713 [TBL] [Abstract][Full Text] [Related]
18. GLP-1 and extra-islet effects. Ahrén B Horm Metab Res; 2004; 36(11-12):842-5. PubMed ID: 15655717 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. D'Alessio DA; Vahl TP Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755 [TBL] [Abstract][Full Text] [Related]
20. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents. Creutzfeldt W Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]